CN110283836A - 3 type duck hepatitis A virus mutated gene ISA-T1142A of one kind and construction method - Google Patents

3 type duck hepatitis A virus mutated gene ISA-T1142A of one kind and construction method Download PDF

Info

Publication number
CN110283836A
CN110283836A CN201910551577.4A CN201910551577A CN110283836A CN 110283836 A CN110283836 A CN 110283836A CN 201910551577 A CN201910551577 A CN 201910551577A CN 110283836 A CN110283836 A CN 110283836A
Authority
CN
China
Prior art keywords
virus
mutated gene
strain
duck hepatitis
type duck
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201910551577.4A
Other languages
Chinese (zh)
Other versions
CN110283836B (en
Inventor
程安春
文兴建
汪铭书
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Agricultural University
Original Assignee
Sichuan Agricultural University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Agricultural University filed Critical Sichuan Agricultural University
Priority to CN201910551577.4A priority Critical patent/CN110283836B/en
Publication of CN110283836A publication Critical patent/CN110283836A/en
Application granted granted Critical
Publication of CN110283836B publication Critical patent/CN110283836B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32411Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32421Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32411Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32422New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32411Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32411Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32461Methods of inactivation or attenuation
    • C12N2770/32462Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention discloses 3 type duck hepatitis A virus mutated gene ISA-T1142A of one kind and construction methods, the G of 3403rd nucleotide of the mutated gene genome sports T, as the genetic marker of infection clones, can be used to distinguish rescue strain and parent plant and street strain;1142nd nucleotide sports A by T, so that make the 164th amino acids of viral VP0 albumen sports asparagine by the tyrosine of parent plant.Mutated gene Strain and parent plant antigenicity having the same, and there is proliferation efficiency more higher than parent plant and virus titer in duck embryos, immunogenicity and genetic stability are good.Mutated gene Strain has been decreased obviously duckling pathogenicity, this has established important foundation for the viral pathogenesis mechanism and vaccine development.In conclusion 3 type duck hepatitis A virus mutated gene ISA-T1142A Strain, which can be used as a candidate strain vaccine or cultivation strain and can be used for 3 type duck hepatitis A virus, causes weak mechanism study, have a extensive future.

Description

3 type duck hepatitis A virus mutated gene ISA-T1142A of one kind and construction method
Technical field
The invention belongs to gene engineering technology fields, and in particular to 3 type duck hepatitis A virus mutated gene ISA- of one kind T1142A and construction method.
Background technique
Duck virus hepatitis (Duck viral hepatitis, DVH) is by duck hepatitis virus (Duck hepatitis Virus, DHV) one kind is acute, highly contagious disease caused by infection duckling.Current duck culturing area main in the world has The presence of this disease has the characteristics that interval outburst, endemicity, is to endanger one of principal disease of duck culturing industry.The disease is main The duckling within four week old is encroached on, has morbidity anxious, is propagated rapidly, the features such as course of disease is short and the death rate is high;Clinical manifestation For the dead preceding generation spasm of duckling, head is swung back to back, is in " opisthotonos ", and pathological change is mainly the visible liver enlargement hair of dissect Scorching and a large amount of haemorrhagic puncta.The disease is mainly by belonging to the duck hepatitis A virus (Duck of Picornaviridae fowl hepatovirus Hepatitis A virus, DHAV) cause.There are three types of serotype, i.e. 1 type, 2 types and 3 types for DHAV tool.In recent years, China is flowed Capable DHAV is mainly 1 type duck hepatitis A virus (DHAV-1) and 3 type duck hepatitis A virus (DHAV-3).
Reverse genetics manipulation technology is a kind of Important Platform for carrying out viral molecular biology research, can be right in vitro Rna virus cdna group carries out the manual operations such as gene knockout, direct mutagenesis, the energy in illustrating viral pathogenesis mechanism and vaccine development It enough plays a significant role and has the advantage shorter than the natural mutagenesis period.The key of traditional picornavirus infection cloning process is to obtain Full-length cDNA full length fragment clone, and viral genome be converted to cDNA after need to be cloned into suitable carrier In, in order to avoid instability problem of the virus sequence in bacterium, researcher is usually taken cDNA clones method, passes through small fragment Large fragment is connected into, large fragment is finally obtained into full length cDNA clone by the method that digestion connects.But this method digestion position It is more that point chooses limitation, and multiple large fragments are attached to efficiency is lower, and other rdrp gene cDNA clone exists in vitro There is unstability, therefore not only operating procedure is troublesome for the whole process of acquisition full length viral genome cDNA in bacterium, but also It taking a long time, success rate is not high, meanwhile, although the full-length cDNA of some viruses can not be cloned or can be cloned into carrier in place It easily morphs in main bacterium and leads to the Revive virus that cannot succeed.Currently, a kind of be referred to as " infectious Subgenomic replicon The technology of (Infectious Subgenomic Amplicons) " has been shown to real in mammal or mosquito cells Now to the artificial rescue of single strand plus RNA virus, and it is applied to japanese encephalitis virus, west nile virus, zika virus, yellow heat In the reverse genetics research of the virus such as virus, dengue virus and people's coxsackie virus.The technology is a kind of novel " without thin Bacterium " reverse-genetics approach does not need to obtain virus full length cDNA plasmid and obtains transcription of viral RNA sheet in vitro, can be with Directly there is by transfection the DNA fragmentation Revive virus of homology region.For specific, " infectious sub-genome duplication The technology path that son " uses is: generating the non-infectious subunit comprising entire virus genomic overlapping by PCR method first Because of a group DNA fragmentation, the Subgenomic replicon quantity of these overlappings can be 3 to 10, have between adjacent replicon The overlapping region of 100bp or so, meanwhile, the 5' of first segment and the end 3' of the last one segment flank giant cell disease respectively Malicious early promoter (Cytomegalovirus immediate early promoter, pCMV) sequence, Hepatitis D virus Ribozyme (Hepatitis delta virus ribozyme, HDVR) sequence and vacuolating virus of monkey early stage mRNA polyadenylation letter Number (SV40 early mRNA polyadenylation signal, SV40pA) sequence, these elements can help sub-gene Group replicon be mixed be transfected into permissive cell after start to transcribe, and using host cell homologous recombination machinery it is spontaneous heavy Group, being formed has infective intact virus transcript, then leads to the duplication and proliferation of virus, and final obtain has infectivity Revive virus.
DHAV-1 attenuated vaccine mainly is used to the prevention and control of DHAV on Vehicles Collected from Market, still lacks efficient DHAV-3 epidemic disease living Seedling is researched and developed and is suitble to the New molecular marker vaccine of China DHAV-3 popularity extremely urgent;Meanwhile studying the variation of DHAV virulence Viral gene and the basic research such as critical sites can provide theoretical foundation for the prevention and treatment of duck hepatitis, also there is an urgent need to obtain poison for this The Strain of power variation.
Summary of the invention
The technical problem to be solved by the present invention is to, using genetic modification platform obtain 3 type duck hepatitis A virus vaccine candidates or Cultivate strain;Meanwhile the Strain for obtaining virulence variation can be the viral gene of research DHAV virulence variation and critical sites etc. Basic material is provided.
In order to achieve the above technical purposes, the present invention is realized especially by following technical scheme:
3 type duck hepatitis A virus mutated gene ISA-T1142A of one kind, the mutated gene ISA-T1142A is with 3 type ducks 1142nd nucleotide of hepatitis A virus velogen strain genome sports A by T, to make the 164th bit amino of its VP0 albumen Acid sports asparagine by the tyrosine of parent plant.
The 3 type duck hepatitis A virus (Duck Hepatitis A Virus type 3, DHAV-3) are preserved in China Type Tissue Collection, deposit number are CCTCC NO:V201305, preservation address: Wuhan City, Hubei Province Wuchang District Aug. 1st The Wuhan University of road 299 in the school, preservation date: on March 25th, 2013.
The G of the 3403rd nucleotide of mutated gene genome sports T, the heredity mark as infection clones Note, can distinguish mutated gene and parent plant and street strain by PCR method combination DNA sequencing.
The mutated gene Strain that the present invention contains genetic marker can be steady in 9 age in days duck embryos as parental virus Fixed proliferation passage and virus multiplication titre is higher, genetic stability is good, is not mutated for continuous passage 10 times.
The present invention contains the mutated gene Strain of genetic marker relative to parental virus, and mutated gene is to duckling pathogenicity It has been decreased obviously.
In another aspect of this invention, application of the above-mentioned mutated gene in preparation duck hepatitis virus vaccine is provided.
The mutated gene can be also used in duck hepatitis virus virulence and cause in weak Study on Molecular Mechanism simultaneously.
In another aspect of this invention, the construction method of above-mentioned mutated gene Strain is provided, comprising the following steps:
(1) parental virus full-length genome is divided into (2.6kb, 2.6kb and 2.7kb) three segments similar in size to carry out PCR amplification adds cytomegalovirus early promoter (Cytomegalovirus at the end 5' of first segment of viral genome Immediate early promoter, pCMV) mutational site, the 2A gene of second segment are introduced in sequence and VP0 gene Middle introducing nonsense mutation adds Hepatitis D virus core as genetic marker site, at the end 3' of viral genome the third fragment Enzyme (Hepatitis delta virus ribozyme, HDVR) sequence and vacuolating virus of monkey early stage mRNA polyadenylation signal (SV40 early mRNA polyadenylation signal, SV40pA) sequence obtains three DNA fragmentations and constitutes 3 type ducks Hepatitis A virus mutated gene ISA-T1142A " infectious Subgenomic replicon ";
(2) by 3 type duck hepatitis A virus mutated gene ISA-T1142A " infectious Subgenomic replicon " of building with turn Duck embryo fibroblasts are transfected after transfection reagent mixing, replicon transcribes in host cell and utilizes the homologous recombination machinery of cell Spontaneous recombination, being formed has infective intact virus transcript, then leads to the duplication and proliferation of virus, is finally contained 3 type duck hepatitis A virus ISA-T1142A mutant strains of genetic marker.
Further, first segment and the third fragment contain 74 and 83 base-pairs with second segment respectively Overlapping region.
The invention has the benefit that
1,3 type duck hepatitis A virus mutated genes are obtained than natural method mutagenesis and conventional counter heredity using the method for the present invention The time cycle of operating technology is short, can accelerate the cultivation and viral pathogenesis Mechanism Study of 3 type duck hepatitis A virus attenuated vaccine strains Process.
2, the mutated gene ISA-T1142A Strain obtained in the present invention has antigenicity similar with its parent's strain, Therefore the mutated gene Strain can be used as 3 type duck hepatitis A virus vaccine candidate vaccines or cultivate strain;It is in duck embryos simultaneously The speed of growth is faster than parent plant, has more high titre in duck embryos, as yield can be improved, reduce cost in production of vaccine.
3, since the mutated gene ISA-T1142A Strain obtained in the present invention is compared with parent plant, virulence is reduced, because This can be used in its further cultivation as duck hepatitis virus attenuated vaccine strain;It can also be used in the disease of duck hepatitis virus virulence variation In the application of the basic research such as virus gene and critical sites.
Detailed description of the invention
Fig. 1 be framework construction molecular labeling mutated gene ISA-T1142A " infectious sub- based on 3 type duck hepatitis A virus The schematic diagram of subgenomic replicons ";
Fig. 2 be 3 type duck hepatitis A virus mutated gene ISA-T1142A " infectious Subgenomic replicon " transfect duck embryos at Fibrocyte result figure;
Fig. 3 is that same sense mutation molecular genetic marker position nucleotide sequencing result is introduced in the 2A gene of mutated gene;
Fig. 4 is the VP0 gene target mutational site nucleotide sequencing result of mutated gene;
Specific embodiment
Embodiment below facilitates a better understanding of the present invention, but does not limit the present invention.Experiment in following embodiments Method is unless otherwise specified conventional method.Test material as used in the following examples unless otherwise specified can be from Commercial sources obtain.
Material and reagent as used in the following examples are specific as follows:
Strain:
3 type duck hepatitis A virus velogen strains: this laboratory is isolated, has been preserved in the Chinese Typical Representative training of Wuhan, China university Support object collection, deposit number are as follows: CCTCC NO:V201305, classification naming: 3 type duck of fowl hepatovirus Picornaviridae Hepatitis A virus (Duck Hepatitis AVirus type 3, DHAV-3).
Reagent and instrument:
TaKaRa MiniBEST Universal RNA Extraction Kit, PrimeSTAR Max DNA Polymerase, DNA Marker etc. is purchased from precious bioengineering (Dalian) Co., Ltd;Plastic recovery kit, plasmid extraction reagent Box etc. is purchased from U.S. Omega company;Lipofectamine box Lipofectamine 3000 is purchased from Invitrogen company;Its His reagent is that domestic analysis is pure.
Nucleic acid-protein detector (Bio Rad, Smartspec 3000), grads PCR instrument (Biometra, Tgradient), Electrophoresis apparatus (Bio Rad, Powerpac 300) and gel imaging system (Bio Rad Versa Doc Model 2000).
The building of 13 type duck hepatitis A virus mutated gene ISA-T1142A " infectious Subgenomic replicon " of embodiment and Virus rescue
1.1. the design and synthesis of primer
According to the whole genome sequence of 3 type duck hepatitis A virus in GenBank, it is viral complete for expanding to devise 7 pairs of primers Genome sequence, pCMV and SV40pA sequence, particular sequence information are shown in Table 1, and primer is by Shanghai Sheng Gong bioengineering Co., Ltd Synthesis.
Table 1 constructs 3 type duck hepatitis A virus mutated gene ISA-T1142A infectivity Subgenomic replicon primers
1.2. virus extracting
It is operated referring to the operation instructions of TaKaRa MiniBEST Universal RNA Extraction kit, from The viral full-length genome RNA of 3 type duck hepatitis A virus separation strains is extracted in duck embryos allantoic fluid, and uses nucleic acid-protein detector (Bio Rad, Smartspec3000) measure its nucleic acid concentration and purity after, -70 DEG C save backup.
1.3. gene fragment amplification is cloned
(1) using PrimeScript II 1st Strand cDNA Synthesis kit that the total serum IgE of extracting is anti- It is transcribed into cDNA template, DNA High fidelity PCR enzyme PrimeSTAR Max DNA Polymerase is then used, uses primers F 1- F and T1142A-R obtains DHAV-3-F1-T1142A-R piece by template amplification of the reverse transcription product of parent plant virus total RNA Section, obtains DHAV-3-F1- as template amplification using the reverse transcription product of parent plant virus total RNA using T1142A-F and F1-R T1142A-F segment, using primers F 2-1-F and F2-1-R, F2-2-F and F2-2-R with the reverse transcription of parent plant virus total RNA Product is that template expand obtain DHAV-3-F2-1 segment and DHAV-3-F2-2 segment respectively, using primers F 3-HDVR-F with F3-HDVR-R obtains DHAV-3-F3-HDVR segment by template amplification of the reverse transcription product of parent plant virus total RNA;With eukaryon Expression plasmid pEGFP-C1 is template, expands to obtain pCMV segment using primer pCMV-F and pCMV-R, uses primer HDVR- SV40pA-F and HDVR-SV40pA-R expands to obtain HDVR-SV40pA segment.
(2) by fusion DNA vaccine technology, as shown in Figure 1, first by DHAV-3-F1-T1142A-F and DHAV-3-F1- T1142A-R segment composition is DHAV-3-F1-T1142A, is then by pCMV and DHAV-3-F1-T1142A segment composition pCMV-F1;It is F2 segment by DHAV-3-F2-1 and DHAV-3-F2-2 segment composition;By DHAV-3-F3-HDVR and HDVR- SV40pA segment composition is F3-HdvRz/SV40pA segment, and three DNA fragmentations finally obtained constitute mutated gene ISA- T1142A " infectious Subgenomic replicon ".Amplified fragments are respectively adopted gel and return after the separation of 1% agarose gel electrophoresis Receive kit (Omega) gel extraction target fragment.DNA fragmentation is sent to Shanghai Sheng Gong bioengineering Co., Ltd and is surveyed Sequence.
1.4. the transfection rescue of mutated gene ISA-T1142A " infectious Subgenomic replicon "
Primary duck embryo fibroblasts are prepared using 9 age in days duck embryos, when the cell in 3.5cm culture dish is grown to When 90% fusion, by pCMV-F1, F2 and F3-HdvRz-SV40pA genetic fragment and Lipofectamine of equivalent (1.5 μ g) 90% duck embryo fibroblasts are covered in transfection after 3000 (Invitrogen) mixing, and Lipofectamine is used only in control group 3000 (Invitrogen) are transfected.Cell is placed in 37 DEG C of 5%CO2Culture observation is carried out in incubator, is replaced after 16 hours Culture medium, after transfection 72 hours, there is cell fragmentation phenomenon in transfection group cell, and cellular control unit upgrowth situation is good.? After transfection duck embryo fibroblasts 120 hours, cell growth condition is as shown in Fig. 2, by cell multigelation 3 after photographing to record Secondary, cell culture fluid is inoculated with 5 piece of 9 age in days duck embryos by allantoic cavity approach, 0.2mL/ pieces, be put into after paraffin sealing in incubator after Continuous to be incubated for, every 8 hours photograph embryo 1 time, the death condition of observation duck embryos after inoculation discards dead duck embryos in 24 hours.As a result Show that duck embryos are dead between 48 hours to 96 hours after inoculation, duck embryos death idiosome bleeding is serious, collects allantoic fluid as the Generation reverse genetic Strain is saved.
The identification and characteristic of 23 type duck hepatitis A virus mutated gene ISA-T1142A Strain of embodiment
2.1. in Revive virus genetic marker identification
It may be from parental virus or the possibility of street strain's pollution in transfection or succeeding generations to exclude Revive virus, Using reverse-genetics approach, 3403 bit bases of mutated gene genome sport T by being mutated G, which does not change 2A egg The composition of Bai Xiangying amino acid, the site can be distinguished as molecular genetic marker site by PCR method combination DNA sequencing Mutated gene Strain and parent plant and street strain.Revive virus passes through limiting dilution assay passage purifying 5 times in duck embryos.From Total serum IgE is extracted in allantoic fluid, expands DNA fragmentation containing mutation sites using F2-F and F2-R primer PCR after reverse transcription, is expanded Increase segment separate through 1% agarose gel electrophoresis, then using gel reclaims kit (Omega) gel extraction, and by DNA piece Section, which is sent to Shanghai Sheng Gong bioengineering Co., Ltd, to be sequenced, and the silencing that the product of sequencing result display amplification contains introducing is prominent Become (G3403T), as shown in figure 3, show we obtain correct Revive virus, rather than parent plant or wild type strains are dirty Dye.
2.2. the genetic stability in Revive virus and its mutational site detects
For observe save out reverse genetic virus whether passage can be proliferated in duck embryos, by the rescue of 1st generation Virus does 1:100 dilution with sterile saline, is inoculated with 5 piece of 9 age in days duck embryos.The duck embryos death time concentrates on being inoculated with as the result is shown Afterwards between 24 hours to 48 hours, idiosome lesion is obvious, and continuous passage 10 times, during which collects every generation virus liquid, is put in -80 DEG C refrigerator saves.RNA is extracted using the generation virus liquid of the 1st, 5 and 10, after reverse transcription is cDNA, PCR amplification is containing mutation sites DNA fragmentation, and mutational site and genetic marker site are detected, as shown in figure 4, sequencing result shows the 1st, 5 and 10 Generation poison is not mutated, shows that this viral genetic has good stability.
2.3. virus multiplication and assay
With 3 type duck hepatitis A virus Revive virus of sterile saline solution doubling dilution and parent plant, 10 are selected-3、10-4、 10-5、10-6、10-7、10-8This 6 dilutions are inoculated with the duck of 5 piece of 9 age in days with the amount of every embryo 0.2mL through allantoic cavity approach respectively Embryo separately sets sterile saline and compares 5 pieces, and inoculation is placed in 37 DEG C of constant incubators and is incubated for, and dead duck embryos are not in 24 hours Meter, observes and records the death and survival condition that duck embryos are inoculated in 7 days, calculates ELD50 by Reed-Muech method, as the result is shown Revive virus has different proliferative capacities from parent's strain virus, and viral level is respectively 10 in every 0.2mL allantoic fluid- 7.55ELD50 and 10-4.50ELD50。
The result shows that the proliferative capacity of 3 type duck hepatitis A virus mutated gene ISA-T1142A Strain is significantly stronger than parent Strain, as can be increased yield for antigen production in vaccine, reduce cost.
2.4. the antigenicity of serum neutralization test detection virus
Mature progeny viral particles and virus antigenicity whether are generated in duck embryos passage for detection reverse genetic strain Whether change.Using fixed virus diluted blood heat-clearing method measurement 3 type duck hepatitis A virus serum of rabbit-anti to mutated gene Strain With the neutralization titer of parent plant, the 3 type duck hepatitis A virus standard serum of rabbit-anti for first preparing laboratory early period where inventor (potency >=1:128) makees 10 times of doubling dilutions from 2 with sterile saline-1To 2-9This 9 dilutions, while by viral dilution Both then contain 200ELD50 at each unit dose (0.2mL), mixed in equal amounts and be added dual anti-37 DEG C of penicillin and streptomycin of 5% Water-bath hour, then in 9 age in days health duck embryos allantoic cavity of the dose inoculation of every embryo 0.2mL, each dilution is inoculated with 5 pieces of ducks Embryo.Separately setting negative serum control group (healthy rabbit anteserum with virus mix) and blank control group, (sterile saline is mixed with virus Close), the case where discarding duck embryos dead in 24 hours, observe and record the duck embryos death and survival in 7 days, then calculate rabbit-anti Neutralization titer of the 3 type duck hepatitis A virus standard serums to virus.
The result shows that Revive virus and parent's strain virus antigenicity having the same, negative serum control group (Healthy Rabbits blood Mix with virus clearly) and the duck embryos of blank control group (sterile saline with viral mix) it is complete to 48 small times at 24 hours Portion is dead;When serum dilution is 2-1To 2-6Between when, in mutated gene Strain and parent plant and the duck embryos of group are all strong It is living, when dilution is 2-7When duck embryos start to lose protection, start at this time, higher with dilution, duck embryos protective rate is lower, until dilute Degree of releasing is 2-9When duck embryos thoroughly lose protection.Show that 3 type duck first can also be protected by such as preparing vaccine antigen with mutated gene Strain Hepatovirus infection.
2.5. to the Virulence detection of susceptible duckling
Safety testing is carried out using parent plant and mutated gene Strain, acquires the liver of dead duck embryos in embodiment 2.3 Dirty tissue homogenized, sterile phosphate buffer solution is added in the ratio of 1:100 by volume, grinds, multigelation 3 times, 12000g is centrifuged 10min, and supernatant is inoculated with 9 age in days duck embryos through allantoic cavity approach after 0.22 μm of filter filtration sterilization and measures it Then virus liquid is diluted to 10 by ELD503.0ELD50/0.4mL.In addition 1 age in days health duckling 30 is only randomly divided into 3 groups, examination The duckling for testing group is inoculated with 0.4mL parent plant through intramuscular injection path or mutated gene Strain, the duckling of control group are then inoculated with Volume sterile saline, the isolated rearing in different animals room, free water feeding are observed daily after inoculation, record duckling Morbidity, death condition, timely dissect death duckling, dissect is survived duckling after observation 7 days, record duckling liver, the devices such as kidney The lesion situation of official.
7 days internal reference group ducklings do not occur clinical symptoms, and duckling feed and drinking-water situation are normal, duckling after parent plant inoculation Disease incidence 80%, the death rate 60%;And mutated gene Strain pathogenicity has been decreased obviously, duckling disease incidence after inoculation 50%, the death rate 30%, and virus is detected in cloacal swab, show that the success of mutated gene Strain is multiple in duckling body System, and mutated gene Strain and parent plant can be distinguished by PCR method combination DNA sequencing.Therefore, mutated gene Strain With the potentiality further cultivated as duck hepatitis virus attenuated vaccine strain;And virulence is changed, mutated gene virus Strain can be used as the basic material of the researchs such as viral gene and its critical sites of the variation of duck hepatitis virus virulence.
33 type duck hepatitis A virus mutated gene ISA-T1142A Strain of embodiment is preparing the application in inactivated vaccine
There is higher proliferation efficiency than parent plant in duck embryos according to the mutated gene Strain measured in embodiment 2 And virus titer;Immunogenicity and genetic stability are good;Duckling pathogenicity has been decreased obviously, has shown mutated gene ISA- T1142A Strain can be used as a strain vaccine Candidate Strain and be used to prepare 3 type duck hepatitis A virus vaccines.
The preparation method of 3.1 inactivated vaccines
Using 3 type duck hepatitis A virus mutated gene ISA-T1142A Strain as the sterile saline dilution 100 of kind of poison Times, allantoic cavity is inoculated with 20 piece of 9 age in days duck embryos, and every embryo 0.2mL sets in 37 DEG C of constant incubators and continues to be incubated for, 24 hours after inoculation Afterwards according to egg 1 time, dead germ is discarded, later every 8 hours photograph egg 1 time, dead duck embryos are taken out at any time, until 48 hours, duck embryos are complete Portion is dead, and the duck embryos gas chamber of collection is upright upwards, 4 DEG C of coolings 8 hours is placed in, by sterile collection duck embryos allantois after cooling Liquid is placed in -20 DEG C and saves backup.
Virus liquid is handled using final concentration of 0.1% formalin, 37 DEG C inactivate 24 hours, then use sterile physiological Viral level is diluted to 10 by salt water3It emulsifies mixing after ELD50/0.1mL in equal volume with incomplete Freund's adjuvant, that is, 3 types is made Duck hepatitis A virus mutated gene Strain inactivated vaccine.
3.2 sterile and detection of mycoplasma
Inactivated vaccine is carried out sterile and mycoplasma according to existing " Republic of China Veterinary Pharmacopoeia " annex to examine, detection Result is feminine gender.
The detection of 3.3 exogenous virus
Inactivated vaccine is subjected to exogenous virus detection, testing result according to existing " Republic of China Veterinary Pharmacopoeia " annex It is feminine gender.
The safety detection of 3.4 inactivated vaccines
For the safety for examining vaccine, 10 1 age in days ducklings are immunized with 10 times of immunizing doses, every is inoculated with through leg muscle Approach is inoculated with 0.2mL, while taking 10 duckling injection sterile salines as a control group, isolated rearing, free water feeding, The health condition of duckling is observed and recorded daily, and observation analysed duckling after 7 days, and as a result immune group and control group duckling were in inoculation 7 days Inside without morbidity, and analyse the results show that not occurring pathological change in each immune organ of duckling and virus tropism tissue, and let out It grows in chamber swab and virus is not detected, show that inactivated vaccine is not pathogenic to 1 age in days duckling.
The immune efficacy of 3.5 inactivated vaccines
1 age in days duckling 20 is only randomly divided into 2 groups, and 10 ducklings of inactivated vaccine inoculation group are through leg muscle injecting pathway It is inoculated with the above-mentioned vaccine immunity being prepared of a plumage part, another group of injection equivalent sterile saline is as control, two groups of ducklings The case where isolated rearing, free water searches for food, observes and records duckling after inoculation daily, with 10 times of LD50 dosage parent plants after 7 days It carries out attacking poison, attacks after poison and observe and record morbidity, the death condition of duckling daily, timely dissect death duckling, continuous observation 1 week, Dissect survival duckling, the lesion situation of record liver, kidney and other organs.
Experimental group and negative control group duckling do not occur clinical symptoms, duckling feed and drinking-water situation in 7 days after immune Normally.The 2nd day negative control group has duckling lassitude after attacking poison, nervous symptoms occurs, until the 7th day, totally 6 death, survival Duckling has the lesions such as different degrees of liver bleeding, disease incidence 80% (8/10), the death rate 60% (6/10);And inactivated vaccine is exempted from Epidemic disease group duckling is dead without morbidity, and normal water feeding shows that the inactivated vaccine prepared with mutated gene Strain is safe and effective, can Homologous virulent poison is attacked to protect.
The foregoing is only a preferred embodiment of the present invention, is not intended to restrict the invention, although referring to aforementioned reality Applying example, invention is explained in detail, for those skilled in the art, still can be to aforementioned each implementation Technical solution documented by example is modified or equivalent replacement of some of the technical features.It is all in essence of the invention Within mind and principle, any modification, equivalent replacement, improvement and so on be should all be included in the protection scope of the present invention.
Sequence table
<110>Sichuan Agricultural University
<120>3 type duck hepatitis A virus mutated gene ISA-T1142A of one kind and construction method
<160> 17
<170> SIPOSequenceListing 1.0
<210> 1
<211> 31
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 1
tagttattaa tagtaatcaa ttacggggtc a 31
<210> 2
<211> 40
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 2
acaccacagc cgctttcaaa cggttcacta aaccagctct 40
<210> 3
<211> 40
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 3
agagctggtt tagtgaaccg tttgaaagcg gctgtggtgt 40
<210> 4
<211> 25
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 4
tcactggatc taacaatgtg gatgc 25
<210> 5
<211> 25
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 5
gcatccacat tgttagatcc agtga 25
<210> 6
<211> 22
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 6
caacctgcca aaagtcaaac ca 22
<210> 7
<211> 26
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 7
attctgttac acctttacgc cccaca 26
<210> 8
<211> 23
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 8
caacctaggt aagtgagcac gat 23
<210> 9
<211> 23
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 9
gtgctcactt acctaggttg gtt 23
<210> 10
<211> 22
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 10
tggcaacttc ctgtctaacc tg 22
<210> 11
<211> 20
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 11
ccttgaacac tggaacccaa 20
<210> 12
<211> 69
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 12
aagtagccca ggtcggaccg cgaggaggtg gagatgccat gccgaccctt tttttttttt 60
ttagggtgg 69
<210> 13
<211> 59
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 13
cggtccgacc tgggctactt cggtaggcta agggagaaga acttgtttat tgcagctta 59
<210> 14
<211> 23
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 14
taagatacat tgatgagttt gga 23
<210> 15
<211> 583
<212> DNA
<213>cytomegalovirus early promoter is sub (pCMV)
<400> 15
tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata tggagttccg 60
cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgcccatt 120
gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca 180
atgggtggag tatttacggt aaactgccca cttggcagta catcaagtgt atcatatgcc 240
aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta 300
catgacctta tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac 360
catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg actcacgggg 420
atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg 480
ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg gtaggcgtgt 540
acggtgggag gtctatataa gcagagctgg tttagtgaac cgt 583
<210> 16
<211> 67
<212> DNA
<213>hepatitis delta virus ribozyme sequence (HDVR)
<400> 16
gggtcggcat ggcatctcca cctcctcgcg gtccgacctg ggctacttcg gtaggctaag 60
ggagaag 67
<210> 17
<211> 122
<212> DNA
<213>vacuolating virus of monkey early stage mRNA polyadenylation signal (SV40pA)
<400> 17
aacttgttta ttgcagctta taatggttac aaataaagca atagcatcac aaatttcaca 60
aataaagcat ttttttcact gcattctagt tgtggtttgt ccaaactcat caatgtatct 120
ta 122

Claims (7)

1. 3 type duck hepatitis A virus mutated gene ISA-T1142A of one kind, which is characterized in that the mutated gene ISA-T1142A A is sported by T with the 1142nd nucleotide of 3 type duck hepatitis A virus velogen strain genomes, to make the 164th of its VP0 albumen Amino acids sport asparagine by the tyrosine of parent plant.
2. a kind of 3 type duck hepatitis A virus mutated gene ISA-T1142A according to claim 1, which is characterized in that described 3 type duck hepatitis A virus velogen strains be preserved in China typical culture collection center, deposit number is CCTCC NO:V201305.
3. a kind of 3 type duck hepatitis A virus mutated gene ISA-T1142A according to claim 1, which is characterized in that described The G of the 3403rd nucleotide of mutated gene genome sport T, the genetic marker as infection clones.
4. the construction method of 3 type duck hepatitis A virus mutated gene ISA-T1142A Strain described in claim 1, feature exist In, comprising the following steps:
1) parental virus full-length genome is divided into three segments similar in size and carries out PCR amplification, at viral genome first Mutational site is introduced in the end 5' addition cytomegalovirus early promoter and VP0 gene of segment, in viral genome third The end the 3' addition hepatitis delta virus ribozyme sequence and vacuolating virus of monkey early stage mRNA polyadenylation signal sequence of segment, obtain Three DNA fragmentations constitute 3 type duck hepatitis A virus mutated gene ISA-T1142A infectivity Subgenomic replicons;
2) 3 type duck hepatitis A virus mutated gene ISA-T1142A infectivity Subgenomic replicons of building are mixed with transfection reagent Duck embryo fibroblasts are transfected after conjunction, replicon transcribes in host cell and utilizes the homologous recombination machinery of cell spontaneous heavy Group, being formed has infective intact virus transcript, then leads to the duplication and proliferation of virus, final to obtain containing heredity mark 3 type duck hepatitis A virus mutated gene ISA-T1142A Strain of note.
5. construction method according to claim 4, which is characterized in that first segment and the third fragment are respectively with second A segment contains the overlapping region of 74 and 83 base-pairs.
6. construction method according to claim 4, which is characterized in that it is prominent to introduce nonsense in the 2A gene of second segment It is changed into as genetic marker site.
7. 3 type duck hepatitis A virus mutated gene ISA-T1142A described in claim 1 is in preparing 3 type duck hepatitis virus vaccines Application.
CN201910551577.4A 2019-06-24 2019-06-24 Type 3 duck hepatitis A virus mutant gene ISA-T1142A and construction method Active CN110283836B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910551577.4A CN110283836B (en) 2019-06-24 2019-06-24 Type 3 duck hepatitis A virus mutant gene ISA-T1142A and construction method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910551577.4A CN110283836B (en) 2019-06-24 2019-06-24 Type 3 duck hepatitis A virus mutant gene ISA-T1142A and construction method

Publications (2)

Publication Number Publication Date
CN110283836A true CN110283836A (en) 2019-09-27
CN110283836B CN110283836B (en) 2021-07-06

Family

ID=68005631

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910551577.4A Active CN110283836B (en) 2019-06-24 2019-06-24 Type 3 duck hepatitis A virus mutant gene ISA-T1142A and construction method

Country Status (1)

Country Link
CN (1) CN110283836B (en)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103382507A (en) * 2013-06-08 2013-11-06 四川农业大学 One-step dual RT-PCR detection kit of 1-type and 3-type duck hepatitis A virus, primer pairs and method thereof
CN104862425A (en) * 2015-06-12 2015-08-26 广西壮族自治区兽医研究所 Double two-temperature RT-PCR (reverse transcription-polymerase chain reaction) detection kit for duck hepatitis viruses I and III
CN104926939A (en) * 2014-11-28 2015-09-23 四川农业大学 Preparation methods for duck hepatitis virus immunogen and hyperimmune serum and application of duck hepatitis virus hyperimmune serum
CN105198970A (en) * 2015-11-02 2015-12-30 四川农业大学 VP (viral protein)0 recombinant protein of DHAV (duck hepatitis A virus)-1 as well as preparation method and application of VP0 recombinant protein
CN105273065A (en) * 2015-11-02 2016-01-27 四川农业大学 1-type duck hepatitis A virus VP2 recombinant protein, ELISA kit and preparation method thereof
CN105330728A (en) * 2015-11-02 2016-02-17 四川农业大学 Duck hepatitis virus polyprotein antigen sense region DHAV-Mag genetic recombination protein and preparation method and application thereof
CN105566449A (en) * 2014-10-15 2016-05-11 普莱柯生物工程股份有限公司 Anti-foot-and-mouth disease vaccine composition and preparation method and application thereof
WO2017041720A1 (en) * 2015-09-09 2017-03-16 清华大学 Mevalonate pathway inhibitor as highly-effective vaccine adjuvant
CN110295149A (en) * 2019-06-24 2019-10-01 四川农业大学 A kind of CH-P60-117C plants of 3 type duck hepatitis A virus of mutant strain and construction method
CN110684781A (en) * 2019-06-24 2020-01-14 四川农业大学 Type 3 duck hepatitis A virus mutant gene ISA-A117C-T1142A and construction method thereof

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103382507A (en) * 2013-06-08 2013-11-06 四川农业大学 One-step dual RT-PCR detection kit of 1-type and 3-type duck hepatitis A virus, primer pairs and method thereof
CN105566449A (en) * 2014-10-15 2016-05-11 普莱柯生物工程股份有限公司 Anti-foot-and-mouth disease vaccine composition and preparation method and application thereof
CN104926939A (en) * 2014-11-28 2015-09-23 四川农业大学 Preparation methods for duck hepatitis virus immunogen and hyperimmune serum and application of duck hepatitis virus hyperimmune serum
CN104862425A (en) * 2015-06-12 2015-08-26 广西壮族自治区兽医研究所 Double two-temperature RT-PCR (reverse transcription-polymerase chain reaction) detection kit for duck hepatitis viruses I and III
WO2017041720A1 (en) * 2015-09-09 2017-03-16 清华大学 Mevalonate pathway inhibitor as highly-effective vaccine adjuvant
CN105198970A (en) * 2015-11-02 2015-12-30 四川农业大学 VP (viral protein)0 recombinant protein of DHAV (duck hepatitis A virus)-1 as well as preparation method and application of VP0 recombinant protein
CN105273065A (en) * 2015-11-02 2016-01-27 四川农业大学 1-type duck hepatitis A virus VP2 recombinant protein, ELISA kit and preparation method thereof
CN105330728A (en) * 2015-11-02 2016-02-17 四川农业大学 Duck hepatitis virus polyprotein antigen sense region DHAV-Mag genetic recombination protein and preparation method and application thereof
CN110295149A (en) * 2019-06-24 2019-10-01 四川农业大学 A kind of CH-P60-117C plants of 3 type duck hepatitis A virus of mutant strain and construction method
CN110684781A (en) * 2019-06-24 2020-01-14 四川农业大学 Type 3 duck hepatitis A virus mutant gene ISA-A117C-T1142A and construction method thereof
WO2020258757A1 (en) * 2019-06-24 2020-12-30 四川农业大学 Mutant strain of type 3 duck hepatovirus ch-p60-117c strain and construction method therefor
US20210008196A1 (en) * 2019-06-24 2021-01-14 Sichuan Agricultural University Duck hepatitis a virus type 3 mutant ch-p60-117c and construction thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
MENG PAN等: "Recovery of duck hepatitis A virus 3 from a stable full-length infectious cDNA clone", 《VIRUS RES》 *
R ZHANG等: "Molecular epidemiology and genetic diversity of duck hepatitis A virus type 3 in Shandong province of China, 2012-2014", 《ACTA VIROL》 *
WEN X等: "Duck hepatitis A virus 3 strain CH-P60, complete genome", 《NCBI GENBANK DATABASE》 *
XINGJIAN WEN 等: "Mutations in VP0 and 2C Proteins of Duck Hepatitis A Virus Type 3 Attenuate Viral Infection and Virulence", 《VACCINES》 *
ZHANG, XUELIAN等: "Comparative liver transcriptome analysis in ducklings infected with duck hepatitis A virus 3 (DHAV-3) at 12 and 48 hours post-infection through RNA-seq", 《VETERINARY RESEARCH》 *
刘帅帅: "鸭甲型肝炎病毒VP0、VP1截短基因的表达及初步应用", 《万方数据》 *
李化东: "血清3型鸭甲型肝炎病毒HuB60株安全性及遗传稳定性研究", 《中国优秀硕士学位论文全文数据库 农业科技辑》 *
王洪海等: "不同甲型肝炎疫苗免疫效果和应急接种适宜技术研究(一) 桦甸市829名4~10岁儿童抗HAV、HBsAg和ALT检测结果分析 ", 《医学动物防制》 *

Also Published As

Publication number Publication date
CN110283836B (en) 2021-07-06

Similar Documents

Publication Publication Date Title
CN110295149B (en) Mutant strain 3 type duck hepatitis A virus CH-P60-117C strain and construction method thereof
CN111228475A (en) Biological product for preventing novel coronavirus
CN112029736B (en) Recombinant pseudorabies virus live vaccine for preventing African swine fever and preparation method thereof
CN112961219B (en) Recombinant adeno-associated virus, mutant thereof, construction method and application thereof
CN110295180B (en) Type 3 duck hepatitis A virus mutant gene ISA-A117C-C4334A and construction method thereof
CN107815469A (en) A kind of recombinant herpesvirus of turkeys and preparation method thereof
CN110684781B (en) Type 3 duck hepatitis A virus mutant gene ISA-A117C-T1142A and construction method thereof
CN109321571A (en) A method of utilizing CRISPR/Cas9 preparation and reorganization porcine pseudorabies virus
CN101260408B (en) Construction method and application of two-color fluorescence report carrier
CN114350615B (en) STAT2 gene deletion cell strain and preparation method and application thereof
CN110218732B (en) African swine fever virus tandem gene, co-expression vector, construction method and application
CN110607324A (en) Dairy cow lysozyme gene mammary gland specificity expression recombinant plasmid and construction method and application thereof
CN109456991B (en) Protocatechuic acid regulated switch system, regulating method and application thereof
CN112852755A (en) Preparation and application of inactivated vaccine of gE/gI gene deletion strain of pseudorabies virus FJ-2012 strain
CN110484546B (en) Type-3 duck hepatitis A virus mutant gene ISA-C4334A and construction method
CN110283835B (en) Type-3 duck hepatitis A virus mutant gene ISA-T1142A-C4334A and construction method thereof
CN110295148A (en) A kind of method of 3 type duck hepatitis A virus reverse genetic strain of rapid build
CN109456992B (en) Protocatechuic acid regulated multifunctional gene expression platform and application thereof
CN110283836B (en) Type 3 duck hepatitis A virus mutant gene ISA-T1142A and construction method
CN110283834B (en) Type 3 duck hepatitis A virus mutant gene ISA-A117C and construction method
CN103131709B (en) Ribonucleic acid (RNA) interference fragment of zinc finger-x (zfx) gene and application of RNA interference fragment in mouse sex control
CA3226725A1 (en) Composition and uses thereof
CN114395017A (en) Preparation method and application of SARS-CoV-2 virus-like particle
CN113652406B (en) Recombinant virus strain for infectious laryngotracheitis of chickens and application thereof
CN110484515B (en) Vaccine vector for preventing FAdV-4 and NDV, and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant